An Update on the Use of Pantoprazole As a Treatment for Gastroesophageal Reflux Disease

Overview

Journal Clin Exp Gastroenterol

Publisher Dove Medical Press

Specialty Gastroenterology

Date 2011 Jun 23

PMID 21694841

Citations 10

Authors

Sony Mathews

Ashley Reid

Chenlu Tian

Qiang Cai

Affiliations

Soon will be listed here.

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

Citing Articles

Repurposing of US-FDA-approved drugs as negative modulators of ubiquitin specific protease-7 (USP7).

Zadi S, Javaid S, Atia-Tul-Wahab , Zafar H, Awais M, Maslennikov I Heliyon. 2024; 10(5):e26345.

PMID: 38468948 PMC: 10925992. DOI: 10.1016/j.heliyon.2024.e26345.

Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort Study.

Gandhi S, Taylor B, Rubens L, Gautam N, Sherman N, Chittuluru K Ther Innov Regul Sci. 2023; 58(1):166-174.

PMID: 37891390 DOI: 10.1007/s43441-023-00582-6.

Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study.

Awasthi A, Chakraborty P, Agrawal N, Sinha A, Pandey A, Maiti A Thyroid Res. 2023; 16(1):15.

PMID: 37259094 PMC: 10231962. DOI: 10.1186/s13044-023-00156-6.

Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition.

Kao H, Tsai K, Lin W Int J Med Sci. 2023; 20(6):717-724.

PMID: 37213670 PMC: 10198141. DOI: 10.7150/ijms.82407.

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine.

Abukhalil A, Al Sheikh T, Muallem S, Al-Shami N, Naseef H Patient Prefer Adherence. 2023; 17:749-759.

PMID: 36970301 PMC: 10038207. DOI: 10.2147/PPA.S404139.

References

Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101(8):1900-20. DOI: 10.1111/j.1572-0241.2006.00630.x. View

Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B . Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007; 74(3-4):145-54. DOI: 10.1159/000098792. View

Armstrong D, Pare P, Pericak D, Pyzyk M . Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001; 96(10):2849-57. DOI: 10.1111/j.1572-0241.2001.4237_a.x. View

Revicki D, Wood M, Maton P, Sorensen S . The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998; 104(3):252-8. DOI: 10.1016/s0002-9343(97)00354-9. View

Hogan D, Pratha V, Riff D, Ducker S, Schwartz H, Soffer E . Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Aliment Pharmacol Ther. 2007; 26(2):249-56. DOI: 10.1111/j.1365-2036.2007.03375.x. View

Hollenz M, Stolte M, Labenz J . [Prevalence of gastro-oesophageal reflux disease in general practice]. Dtsch Med Wochenschr. 2002; 127(19):1007-12. DOI: 10.1055/s-2002-28325. View

Scholten T, Teutsch I, Bohuschke M, Gatz G . Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig. 2007; 27(4):287-96. DOI: 10.2165/00044011-200727040-00008. View

Enck P, Dubois D, Marquis P . Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999; 231:48-54. DOI: 10.1080/003655299750025264. View

Ra A, Tobe S . Acute interstitial nephritis due to pantoprazole. Ann Pharmacother. 2004; 38(1):41-5. DOI: 10.1345/aph.1D085. View

10.

Pare P, Armstrong D, Pericak D, Pyzyk M . Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol. 2003; 37(2):132-8. DOI: 10.1097/00004836-200308000-00008. View

11.

Gallo S, Dibildox M, Moguel A, Di Silvio M, Rodriguez F, Almaguer I . [Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group]. Rev Gastroenterol Mex. 1999; 63(1):11-6. View

12.

Siller-Matula J, Spiel A, Lang I, Kreiner G, Christ G, Jilma B . Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2008; 157(1):148.e1-5. DOI: 10.1016/j.ahj.2008.09.017. View

13.

Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I . Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?. Scand J Gastroenterol. 1993; 28(8):681-7. DOI: 10.3109/00365529309098272. View

14.

Watson T, Stark J, Vesta K . Pantoprazole-induced thrombocytopenia. Ann Pharmacother. 2006; 40(4):758-61. DOI: 10.1345/aph.1G384. View

15.

Cai Q, Barrie M, Olejeme H, Rosenberg M . A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. Dig Dis Sci. 2007; 53(6):1500-5. DOI: 10.1007/s10620-007-0044-6. View

16.

Tolia V, Bishop P, Tsou V, Gremse D, Soffer E, Comer G . Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006; 42(4):384-91. DOI: 10.1097/01.mpg.0000214160.37574.d3. View

17.

Ehrlich A, Lucker P, Wiedemann A, Sander P, Huber R, Mascher H . Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol. 1999; 21(1):47-51. DOI: 10.1358/mf.1999.21.1.527018. View

18.

Calabrese C, Fabbri A, Di Febo G . Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging. 2007; 2(1):85-92. PMC: 2684091. DOI: 10.2147/ciia.2007.2.1.85. View

19.

DeVault K . Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Expert Rev Gastroenterol Hepatol. 2008; 1(2):197-205. DOI: 10.1586/17474124.1.2.197. View

20.

Shi S, Klotz U . Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64(10):935-51. DOI: 10.1007/s00228-008-0538-y. View